CellPet FT
Product Features
Achieving physical fragmentation of spheroids without enzymatic reactions
- Without enzymatic treatment, spheroids are fragmented into uniform sizes through physical processing in a closed environment.
- This equipment can be applied to human-derived cancer cells, contributing to the preparation of accurate cell concentration gradient suspensions for drug discovery screening. (Refer to the relevant study here.) Furthermore, it has been reported that the clinical characteristics of human-derived cancer cells are maintained in passaging cultures after small fragmentation, as no enzymes are used.
Examples of fragmentation of various human-derived cancer tissues and their subsequent cultures.
| Tumor Tissue | Before fragmentation | After fragmentation | Cell culture after fragmentation |
| Lung cancer |  |
 |
 |
| Ovarian cancer |  |
 |
 |
| Endometrial cancer |  |
 |
 |
| Colorectal cancer |  |
 |
 |
Data provided by Professor Motoki Takagi, Fukushima Medical University
For more information on the use of CellPet FT® for cancer tissue-derived cell types, please visit the website of the Center for Translational Research in Medicine and Industry, Fukushima Medical University
Cell Small Fragmentation Technology
Photograph of human iPS cells after fragmentation.
The fragmented cells can be used for expanded culture, cryopreservation, analysis, and other purposes.
Related Papers
Tamura et al. Evaluation of anticancer agents using patient-derived tumor organoids characteristically similar to source tissues. Oncol Rep. 2018 Aug;40(2):635-646.
DOI: 10.3892/or.2018.6501. Epub 2018 Jun 18.
Takahashi N et al.An In Vitro System for Evaluating Molecular Targeted Drugs Using Lung Patient-Derived Tumor Organoids. Cells. 2019 May 20;8(5):481.
DOI: 10.3390/cells8050481.
Takahashi N et al. Construction of in vitro patient‑derived tumor models to evaluate anticancer agents and cancer immunotherapy. Oncol Lett. 2021 May;21(5):406.
DOI: 10.3892/ol.2021.12667.
Product Specifications
CellPet FT®
|
Model |
CELLPET FT/MA-2.1 |
|
|---|---|---|
|
Fragmentation rate (Suspension flow velocity) |
0.1~0.5 ml/sec in 0.1 ml/sec increments |
|
|
Useable vessel |
・CellPet FT® (and CellPet 3D-iPS®) dedicated |
|
|
Fragmentation mesh |
Opening sizes: 40 µm / 70 µm / 100 µm |
|
| Size |
Width 220 mm × Depth 200 mm × Hight 597 mm |
|
|
Weight |
11.9 kg |
|
|
Ambient temperature |
10～35 degrees Celsius |
|
|
Ambient humidity |
Relative humidity 30 ～80 % |
|
Controller for CellPet FT® (Included with the main unit)
|
Model |
CELLPET FT/ CO-2.1 |
|
|---|---|---|
|
CellPet FT® maximum number of connections |
3 units |
|
|
Display monitor |
6.5 inch touch panel LCD |
|
| Size |
Width 200 mm × Depth 303 mm × Hight 140 mm |
|
|
Weight |
4.3kg |
|
|
Input power |
AC100 V 50/60 Hz 0.1 A | |
|
Ambient temperature |
10～35 degrees Celsius |
|
|
Ambient humidity |
Relative humidity 30～80 % |
|